Loncastuximab
- Generic Name
- Loncastuximab
Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
• Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response.
• The combination therapy showed particularly strong efficacy in ABC DLBCL subtype patients, achieving an 83% disease control rate with 4 responses and 1 stable disease out of 6 patients.
• Safety profile reveals grade 3 or higher adverse effects in 55.6% of patients, while genetic analysis indicates efficacy independent of MYD88 or CD79B mutations.
Targeting CD30 in Diffuse Large B-Cell Lymphoma: Where Does It Fit in?
The treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has evolved with the introduction of anti-CD19 CAR T-cell therapy and other novel agents. Despite these advancements, challenges such as patient eligibility, access to care, and treatment logistics persist. A phase III trial, ECHELON-3, evaluated the efficacy of Brentuximab vedotin (BV) combined with lenalidomide and rituximab (R) in patients with R/R DLBCL, showing improved overall survival compared to placebo plus Len + R. However, the study raises questions about the role of CD30 targeting in DLBCL treatment and the optimal sequencing of therapies.
Lisocabtagene Maraleucel Shows Promise in Relapsed/Refractory Lymphomas
• Lisocabtagene maraleucel (liso-cel) demonstrates efficacy and safety in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL), aligning with pivotal trial outcomes.
• The TRANSCEND FL trial indicates liso-cel achieved a significant overall response rate in relapsed/refractory marginal zone lymphoma (MZL), meeting the primary endpoint.
• Five-year data from TRANSCEND-NHL-001 underscore the curative potential of liso-cel in third-line LBCL, showing a 38% overall survival rate.
• Real-world data supports liso-cel's effectiveness across diverse LBCL patient subgroups, reinforcing its role as a standard-of-care treatment option.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath